title: The contribution of prostatic acid phosphatase and prostatic specific antigen in the diagnosis of prostatic cancer.
abstract: Prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) were measured by immunochemical methods using test preparations from two different companies. In 66 patients with benign hyperplasia of the prostate a good correlation was found only between PSA levels (orthogonal regression analysis: y = 1.77 x -0.68; r = 0.995). Discrimination analysis between benign hyperplasia and new prostatic cancer (28 patients), using ROC curves, revealed a sensitivity for prostatic cancer of about 30 percent using both PAP methods and of about 58 percent using both PSA methods at the 95-percentile of benign hyperplasia. The PSA methods were both more sensitive in detecting prostatic cancer than the PAP methods.
authors: Department of Nuclear Medicine, Bleuland ziekenhuis, Gouda, The Netherlands.
authors: A
authors: A
authors: van Dalen
authors: D H
authors: DH
authors: Helmhout
authors: R D
authors: RD
authors: van Caubergh
mesh_terms: D000135:Acid Phosphatase / Q000097:blood*; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D006965:Hyperplasia; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000201:enzymology; D011863:Radioimmunoassay
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen